**Summary**
Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have been shortlisted as finalists for the 2026 Excellence in Healthcare Partnership (EHP) Awards in the category of Partnership Working to Address National Healthcare Priorities (Local Projects). This recognition highlights their successful collaboration in reducing surgical site infections (SSIs) using Ondines Steriwave® nasal photodisinfection technology. The partnership has demonstrated a 71% reduction in post-surgical infections in hip replacement surgeries and no SSIs in knee surgeries during the evaluation period, alongside significant cost savings for the NHS.
This is the second national award shortlist for the partnership, following their earlier nomination for the HSJ Partnership Award. The Steriwave® technology, which rapidly destroys bacteria, viruses, and fungi without generating resistance, is being adopted by several major hospitals across England and is available through Ondines distribution partner, Mölnlycke Health Care. The EHP Awards celebrate collaborations that align with national healthcare priorities, including patient safety, antimicrobial stewardship, and system efficiency.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, with Steriwave® approved in multiple countries and undergoing clinical trials in the U.S. for regulatory approval. This recognition underscores the potential of nasal photodisinfection as a critical tool in addressing healthcare-associated infections and antimicrobial resistance.